Trevi Therapeutics to Participate in Upcoming September Events

2023-09-06

NEW HAVEN, Conn., Sept. 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following events in September. European Respiratory Society (ERS) International Congress 2023 September 9-13, Milan, Italy 2023 SVB Securities Biopharma Summit September 20-22, Montecito, CA 2023 Cantor Global Healthcare Conference September 26-28, New York, NY Corporate Presentation: Tuesday, September 26th, 4:55 PM ET Presenter: Jennifer Good, President and CEO About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis. Haduvio is a dual ĸ-opioid receptor agonist ĸ-opioid receptor agonist and µ-opioid receptor antagonist µ-opioid receptor antagonist that works both centrally as well as peripherally in the lungs and has the potential for a synergistic anti-tussive effect to treat chronic cough. The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. Parenteral nalbuphine is not scheduled by the US Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on Twitter and LinkedIn. Investor Contact Katie McManus Trevi Therapeutics, Inc. 203-304-2499 k.mcmanus@trevitherapeutics.com Company Codes: NASDAQ-NMS:TRVI

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构